Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial | Zendy

Bart Jan Kullberg | Zendy; Claudio Viscoli | Zendy; Peter G. Pappas | Zendy; José A. Vázquez | Zendy; Luis OstroskyZeichner | Zendy; Coleman Rotstein | Zendy; Jack D. Sobel | Zendy; Raoul Herbrecht | Zendy; Galia Rahav | Zendy; Sutep Jaruratanasirikul | Zendy; Ploenchan Chetchotisakd | Zendy; Eric Van Wijngaerden | Zendy; Jan J. De Waele | Zendy; Christopher Lademacher | Zendy; Marc Engelhardt | Zendy; Laura Kovanda | Zendy; Rodney CroosDabrera | Zendy; Christine Fredericks | Zendy; George R. Thompson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial

Author(s) -

Bart Jan Kullberg,

Claudio Viscoli,

Peter G. Pappas,

José A. Vázquez,

Luis OstroskyZeichner,

Coleman Rotstein,

Jack D. Sobel,

Raoul Herbrecht,

Galia Rahav,

Sutep Jaruratanasirikul,

Ploenchan Chetchotisakd,

Eric Van Wijngaerden,

Jan J. De Waele,

Christopher Lademacher,

Marc Engelhardt,

Laura Kovanda,

Rodney CroosDabrera,

Christine Fredericks,

George R. Thompson

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy827

Subject(s) - caspofungin , medicine , voriconazole , clinical endpoint , population , randomized controlled trial , adverse effect , surgery , antifungal , environmental health , dermatology

Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research